Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Gene | CSF1R |
| Variant | R549_E554delinsQ |
| Impact List | indel |
| Protein Effect | gain of function - predicted |
| Gene Variant Descriptions | CSF1R R549_E554delinsQ results in a deletion of six amino acids in the regulatory juxtamembrane domain of the Csf1r protein from amino acids 549 to 554, combined with the insertion of a glutamine (Q) at the same site (UniProt.org). R549_E554delinsQ results in increased ligand-independent phosphorylation of Akt and Erk in culture (PMID: 34978715), and therefore, is predicted to lead to a gain of Csf1r protein function. |
| Associated Drug Resistance | |
| Category Variants Paths |
CSF1R mutant CSF1R act mut CSF1R R549_E554delinsQ |
| Transcript | NM_001288705.3 |
| gDNA | chr5:g.150061816_150061830del15 |
| cDNA | c.1646_1660del15 |
| Protein | p.R549_E554delinsQ |
| Source Database | RefSeq |
| Genome Build | GRCh38/hg38 |
| Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
|---|---|---|---|---|---|
| NM_005211.4 | chr5:g.150061816_150061830del15 | c.1646_1660del15 | p.R549_E554delinsQ | RefSeq | GRCh38/hg38 |
| NM_005211.3 | chr5:g.150061816_150061830del15 | c.1646_1660del15 | p.R549_E554delinsQ | RefSeq | GRCh38/hg38 |
| NM_001375320.1 | chr5:g.150061816_150061830del15 | c.1646_1660del15 | p.R549_E554delinsQ | RefSeq | GRCh38/hg38 |
| NM_001288705.3 | chr5:g.150061816_150061830del15 | c.1646_1660del15 | p.R549_E554delinsQ | RefSeq | GRCh38/hg38 |
| NM_001349736.1 | chr5:g.150061816_150061830del15 | c.1646_1660del15 | p.R549_E554delinsQ | RefSeq | GRCh38/hg38 |
| NM_001349736.2 | chr5:g.150061816_150061830del15 | c.1646_1660del15 | p.R549_E554delinsQ | RefSeq | GRCh38/hg38 |
| NM_001288705.2 | chr5:g.150061816_150061830del15 | c.1646_1660del15 | p.R549_E554delinsQ | RefSeq | GRCh38/hg38 |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| CSF1R R549_E554delinsQ | Erdheim-Chester disease | predicted - sensitive | Pexidartinib | Case Reports/Case Series | Actionable | In a clinical case study, Turalio (pexidartinib) resulted in a complete clinical and metabolic response lasting more than 1.5 years in a patient with Erdheim-Chester disease harboring CSF1R R549_E554delinsQ (PMID: 34978715). | 34978715 |